Agilent Technologies delivered a strong finish to fiscal year 2025, reporting Q4 revenue of $1.86 billion, which grew 7.2% on a core basis and 9.4% on a reported basis, marking the sixth consecutive quarter of core growth acceleration. Earnings per share reached $1.59, a 9% increase year-over-year, driven by robust operational execution that yielded over 200 basis points of sequential operating margin expansion to 27.2%. Performance was broad-based, with double-digit contributions from key regions and strong momentum in LC and LCMS instruments, fueled by the Infinity 3 and Pro IQ launches, as well as a >40% core growth surge in the specialty CDMO business (BioVectra). Looking ahead to FY 2026, the company provided initial guidance of 4% to 6% core revenue growth ($7.3-$7.4 billion) and EPS of $5.86 to $6.00 (5-7% growth), projecting 75 basis points of operating margin expansion despite a 250 basis point headwind from global tax reforms.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $1.86 Billion | +7.2% Core / +9.4% Reported |
| Q4 EPS | $1.59 | +9% YoY |
| Q4 Operating Margin | 27.2% | +>200bps Sequential |
| Q4 Gross Margin | 54.1% | +100bps Sequential |
| BioVectra CDMO Growth | N/A | >40% Core |
| Pro IQ LCMS Growth | N/A | >50% |
| Book-to-Bill | >1.0 | 7th Consecutive Quarter |
| FY26 Revenue Guidance | $7.3 - $7.4 Billion | +4% to 6% Core |
| FY26 EPS Guidance | $5.86 - $6.00 | +5% to 7% |
The 'Ignite' operating system has emerged as a critical strategic lever, driving over $150 million in annualized savings and enabling significant pricing power, with price growth more than doubling compared to FY '24. This internal transformation facilitated a rapid response to tariff changes, creating a cross-functional task force that management is 'highly confident' will fully mitigate tariff impacts in FY 2026. The success of Ignite underscores Agilent's ability to leverage its scale for operational efficiency, supporting margin expansion even amidst inflationary and tariff pressures.
Agilent is capitalizing on a synchronized product cycle and gaining market share, particularly in LC and LCMS platforms. The Infinity 3 system is delivering 'as much as 30% improvement in productivity,' driving double-digit growth in the second half, while the Pro IQ LCMS achieved 'amazing ramp' with >50% growth in Q4. Additionally, the Alturo BioInert column is seeing adoption 'an order of magnitude greater than past column launches,' specifically targeting high-growth modalities like oligos and GLP-1s.
The BioVectra acquisition is proving to be a significant growth driver, with the specialty CDMO business growing more than 40% on a core basis in Q4 and representing nearly 20% of Life Sciences and Diagnostics Group (LDG) revenue. Management highlighted robust visibility for FY 2026 with a 'very robust order book,' driven by demand for siRNA and GLP-1 manufacturing. Strategic capacity expansion (Train C) is on track for 2027, positioning Agilent to capture long-term growth in the peptide and oligotherapeutic markets.
Management identified a long-term structural opportunity in 'pharma reshoring,' estimating a $1 billion addressable market for Agilent by 2030 as customers consolidate supply chains and increase regional R&D and tech investments. While the order benefit for FY 2026 is expected to be limited, the company is actively engaging with key pharma customers on 'shovels in the ground' lab equipment needs, signaling a potential multi-year growth tailwind beyond the current fiscal year.
Agilent is integrating Artificial Intelligence into both its innovation engine and operational workflows. AI now generates 80% of engineering drawings, reducing custom design cycle times by 75% for GC products, and is being used in order fulfillment to eliminate redundant shifts and reduce downtime. This focus on AI-driven efficiency supports the company's goal of accelerating R&D productivity and improving quality, aligning with the broader strategic priority of 'advancing operational excellence.'
The China market presented a notable downside variance, declining 4% in Q4 against expectations of low single-digit growth. Management has adopted a prudent stance for FY 2026, guiding to a 'flat' performance and explicitly excluding potential benefits from the SAMR tender (approx. $10 million) and other stimulus measures from the current guidance. This suggests that the recovery in China remains sluggish and dependent on unpredictable government policy timing, creating a risk to the upside case if stimulus delays persist.
The Academia and Government end market, though small (~7-8% of revenue), declined 10% in Q4, with US federal spending reductions causing a 'material impact' (instruments down mid-20s in Americas). Guidance anticipates a continued 'low single digit decline' in FY 2026, indicating that headwinds from US federal budget cuts are structural and unlikely to abate in the near term, potentially capping growth in this specific segment.
Agilent faces a significant 250 basis point increase in its tax rate in FY 2026 due to the implementation of Pillar Two (global minimum tax) and other jurisdictional changes (OBADHA). This creates a 3 percentage point headwind on EPS growth. While management expressed confidence in offsetting this through operating performance, the elevated tax rate reduces the margin of error for achieving earnings targets and represents a permanent structural change to the company's tax profile.
Management characterized the FY 2026 revenue guidance of 4-6% as 'prudent,' specifically citing 'unevenness in ongoing recovery dynamics' and 'tougher comps.' This conservatism, combined with the exclusion of China stimulus from the guide, implies that the external macro environment remains volatile. There is a risk that if the biotech funding recovery is slower than anticipated or if the pharma reshoring trend delays, the company may struggle to reach the high end of its growth targets without further macro improvement.
Overall: Management conveyed a tone of disciplined confidence and optimism throughout the call. CEO Padraig McDonnell emphasized the 'structural resilience' of the portfolio and the successful execution of the 'Ignite' operating system, frequently citing specific growth drivers like GLP-1s and replacement cycles. The introduction of new CFO Adam Alanoff was seamless, with both executives highlighting financial discipline and the ability to navigate macro headwinds, particularly tariffs, through strategic pricing and efficiency.
Confidence: HIGH - Management backed their outlook with specific data points, such as 'well over $150 million in annualized savings' from Ignite and 'highly confident' assertions regarding full tariff mitigation in FY 2026. While they described the revenue guidance as 'prudent' due to macro uncertainty, the detailed explanation of margin drivers and product momentum suggests strong internal visibility.
$7.3 - $7.4 billion (4% - 6% Core Growth)
$5.86 - $6.00 (5% - 7% Growth)
+75 basis points expansion at midpoint
14.5% (increase of 250bps vs FY25)
$1.79 - $1.82 billion (4% - 6% Core Growth)
$1.35 - $1.38
Hedging & Uncertainty: Management employed a balanced use of hedging language to temper optimism with prudence. While they used strong, definitive verbs regarding past execution ('delivered,' 'executed exceptionally well'), they shifted to probabilistic language for forward-looking statements, using phrases like 'expect,' 'anticipate,' and 'bodes well.' Notably, CEO Padraig McDonnell used the qualifier 'prudent' to describe the guidance, acknowledging 'macro uncertainty' and 'tougher comps.' However, this hedging was counterbalanced by high-confidence assertions on specific controllable factors, such as being 'highly confident' in tariff mitigation and describing the CDMO order book as 'very robust.' The phrase 'too soon to call an inflection' regarding biotech recovery further illustrates a cautious approach to interpreting early positive signals.
We are highly confident that we will fully mitigate current tariffs in FY '26. - Padraig McDonnell, President and CEO
We believe this range is a prudent initial guide that takes into account secular growth drivers... This allows for unevenness in ongoing recovery dynamics across our markets. - Padraig McDonnell, President and CEO
While it's too soon to call an inflection, the accelerating pace of M&A and improving funding environment... bodes well for our small and midsized biotech customers. - Padraig McDonnell, President and CEO
We're more than offsetting this incremental tax burden, and that's really through operating performance above the line. - Adam Alanoff, CFO
We're expecting that to be more normalized. - Padraig McDonnell, President and CEO
We're taking a prudent approach and substantially moving stimulus benefits from our FY 2026 revenue guidance. - Rodney Gonzalez, VP Controller
Analyst Sentiment: Analysts expressed a generally positive and inquisitive tone, probing for details on the sustainability of the CDMO growth, the mechanics of the GLP-1 exposure, and the specific reasons for the China miss. There was significant interest in the margin structure and the company's ability to maintain expansion amidst tax headwinds and tariff costs.
Management Responses: Management responses were detailed and data-rich, often providing granular metrics (e.g., specific GLP-1 revenue figures, LC vs LCMS growth rates) to support their narrative. They effectively defended the conservative guidance by explaining the exclusion of China stimulus and the early stage of the biotech recovery, while reinforcing confidence in the Ignite operating system to drive efficiency.
BioVectra & CDMO Performance: Analysts sought clarity on the CDMO growth trajectory, capacity expansion plans (Train C), and the integration success. Management confirmed a 'robust order book' for FY26 and strong execution.
China Weakness: Questions focused on the 4% decline and the timing of the SAMR tender/stimulus. Management acknowledged the miss but maintained that market share is stable and stimulus is excluded from the guide.
GLP-1 Exposure: Analysts asked for the size of the GLP-1 business. Management revealed it is ~$130M annually, split between CDMO and analytical tools, with strong growth expected.
Margin & Tariffs: Discussions centered on the 75bps margin guide and the ability to mitigate tariffs. Management emphasized pricing power (>100bps) and cost savings (Ignite) as key enablers.
Tax Rate: Analysts inquired about the 250bps tax rate hike. Management attributed it to Pillar Two/global minimum tax and confirmed it is a permanent structural change.
Agilent Technologies presents a compelling investment case driven by the successful execution of its 'Ignite' operating system, which is driving margin expansion, pricing power, and operational efficiency. The company is benefiting from a robust product cycle, led by Infinity 3 and Pro IQ, that is fueling market share gains in LC/LCMS, while the BioVectra acquisition provides a high-growth vector in the CDMO and GLP-1 markets. Although management has issued a 'prudent' 4-6% growth guide for FY26 that excludes potential China stimulus, the underlying fundamentals—including a >1.0 book-to-bill, strong recurring revenue, and confidence in full tariff mitigation—suggest potential for upside. The transition to new CFO Adam Alanoff appears smooth, maintaining a focus on capital discipline and strategic M&A. The primary risks are persistent weakness in China and US government spending, but these are offset by the structural resilience of the pharma and applied markets.
Management is 'highly confident' in fully mitigating FY26 tariff headwinds through a combination of pricing actions and cost savings generated by the Ignite operating system, effectively neutralizing a major cost overhang.
There are signs of improvement in the biotech funding environment, with 'accelerating pace of M&A' and improved spending from large caps. Pharma reshoring is identified as a $1B opportunity by 2030, though order benefits in FY26 are expected to be limited.
The benefits from China stimulus (e.g., SAMR tender) are being pushed out to later in FY26 or excluded from guidance entirely, resulting in a 'flat' growth assumption for the region and indicating a delay in the expected recovery.
US federal spending reductions are causing a 'material impact' on instrument sales (down mid-20s in Americas), and no meaningful recovery is expected in FY26, representing a persistent structural headwind for the Academia and Government end market.